Division of gastrointestinal medical oncology and neuroendocrine tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Molecular Medicine Program, University of Pavia, Pavia, Italy.
Endocr Relat Cancer. 2023 Apr 26;30(6). doi: 10.1530/ERC-22-0395. Print 2023 Jun 1.
We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis.Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.
我们进行了一项针对伴有分子证实的 SARS-CoV-2 阳性的神经内分泌肿瘤（NEN）患者的回顾性/前瞻性全球研究。2021 年已经发表了关于 INTENSIVE 研究的 85 例患者的初步结果。现在我们报告 2 年的分析结果。在这里，我们报告了 2020 年 6 月 1 日至 2022 年 5 月 31 日期间连续入组的患者数据。在联系的 118 个中心中，有 25 个中心有能力入组，19 个中心在数据截止日期时正在积极入组，共有 280 例患者入组。2020 年，47.5%的患者 SARS-CoV-2 阳性，2021 年为 35.1%，2022 年为 17.4%。COVID-19 诊断的中位年龄为 60 岁。分化良好的肿瘤、无功能、转移性分期和胃肠胰腺（GEP）原发部位代表了大多数 NEN。总的来说，COVID-19 相关肺炎发生在 22.8%的患者中，其中 61.3%的患者需要住院治疗；11 例（3.9%）需要亚重症或重症监护病房治疗，14 例（5%）死亡，其中 11 例（3.9%）与 COVID-19 直接相关。COVID-19 诊断时的糖尿病和年龄>70 岁与 COVID-19 死亡率显著相关，而胸部原发部位与 COVID-19 发病率相关。与 2020 年相比，2022 年住院和肺炎的发生率显著下降。在我们最大的 NEN 患者 COVID-19 系列中，NEN 人群与无论 COVID-19 情况如何的一般 NEN 患者人群相似。然而，老年、非 GEP 原发部位和糖尿病应仔细考虑 COVID-19 发病率和死亡率增加的风险。通过将我们的结果与其他癌症患者 COVID-19 登记处中包含的 NEN 患者的结果整合，可以获得相关信息。
